US launch of drug may lift Dr Reddy’s Labs

| Updated on November 22, 2019


Dr Reddy’s Laboratories on Friday said it has launched generic Doxercalciferol injection used for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, in the US market. According to IQVIA Health data, these products had US sales of around $138 million MAT for the most recent 12 months ending in September 2019, the company said in a statement to the exchanges. Shareholders will closely monitor further developments on this front.

Published on November 22, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like